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The role of the immune system in the neurobiological and
pathophysiological mechanisms mediating psychiatric
symptomotology and cognitive functioning has attracted
increasing attention in recent years. This role is exempli-
fied in the case of patients with chronic viral infections
secondary to substance use disorders and in the use of
cytokines as antiviral therapies [e.g., interferon-alpha
therapy for hepatitis C viral (HCV) infection]. In particu-
lar, the recent methamphetamine epidemic in the United
States has highlighted the risk of contracting human
immunodeficiency viral (HIV) and HCV infections. Not
only do substance use disorders increase the risk of con-
tracting HIV or HCV, they have also been associated with
decreased antiviral therapy utilization and virological
suppression.
Cytokines are involved in signaling that activates the cen-
tral nervous system in brain region-specific and cell type-
specific ways. Emerging pre-clinical and clinical evidence
show that cytokines can interact with different neuro-
transmitter and neuroendocrine systems resulting in cog-
nitive dysfunction (e.g., deficits in memory, attention,
vigilance and learning efficiency) and mood disturbances
(e.g., depression, anxiety, and irritability). There are sev-
eral key questions to address in understanding communi-
cation between the immune system and the brain. For
example, how does the central nervous system recognize
the degree of immune activation taking place in the
periphery and when and how do these immune responses
become pathologic, as in the case of interferon-induced
depression or in HIV-related neurocognitive impairments.
Antidepressants are commonly prescribed for interferon-
induced depression; however, these medications lack effi-
cacy in treating a number of the common side effects asso-
ciated with antiviral therapy, such as fatigue, irritability
and loss of concentration. Other potential treatment strat-
egies for these symptoms could include targeting key com-
ponents of the signaling pathways that underlie the
production or action of cytokines.
The goal of this presentation is to integrate current
research findings in the fields of immunology, neuro-
science and psychiatry to improve care for patients with
substance use disorders and comorbid HIV and/or HCV
infections by identifying critical areas for future study and
interdisciplinary collaborations.
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